|Budget Amount *help
¥24,570,000 (Direct Cost: ¥18,900,000、Indirect Cost: ¥5,670,000)
Fiscal Year 2015: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2014: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
Fiscal Year 2013: ¥5,590,000 (Direct Cost: ¥4,300,000、Indirect Cost: ¥1,290,000)
Fiscal Year 2012: ¥6,110,000 (Direct Cost: ¥4,700,000、Indirect Cost: ¥1,410,000)
|Outline of Final Research Achievements
Here we evaluated the specific drug delivery against atherosclerotic lesions and abdominal aortic aneurysms (AAA). For intimal lesions, Cy5-labeled polymeric micelles and vesicles, with diameters of 40, 100, or 200 nm (PICs-40, PICs-100, and PICs-200, respectively) were intravenously administered to rats after injury to the carotid artery using a balloon catheter. High accumulation of PICs-40 in the induced neointima was confirmed by in vivo imaging, while the accumulation of PICs-100 and PICs-200 was limited, indicating that the size of nanocarriers is a crucial factor for efficient delivery. Similar strategy was applied for AAA, and high accumulation of PICs-100 was confirmed in vivo. Furthermore, drug-incorporated polymeric micelles with diameters similar to that of PICs-40 and PICs-100 showed significant curative effects vs rats with induced neointima and AAA. We consider that this nanocarrier-based drug delivery system could be utilized for the treatment of atherosclerosis.